Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 6 recruiting clinical trials
Myeloproliferative neoplasms with CALR mutations
88549968MPN1001
Phase
NCT06150157
Compound
JNJ-88549968 (CALR mutant × CD3 bispecific Ab) ± ruxolitinib + momelotinib
Relapsed or refractory AML or high-risk MDS
90189892AML1001
Phase
NCT06651229
Compound
JNJ-90189892
Relapsed or refractory AML or high-risk MDS
89853413AML1001
Phase
NCT06618001
Compound
JNJ-89853413 (CD33 × Vδ2 bispecific Ab)
Relapsed or refractory acute leukemia with KMT2A, NPM1, NUP98, or NUP214 gene alterations
cAMeLot-1
Phase
NCT04811560
Compound
Bleximenib (menin inhibitor)
Newly diagnosed
KMT2A-rearranged or
NPM1-mutant AML (ineligible for intensive chemotherapy)
KMT2A-rearranged or
NPM1-mutant AML (ineligible for intensive chemotherapy)
cAMeLot-2
Phase
NCT06852222
Compound
Bleximenib (menin inhibitor) + venetoclax + azacitidine
Newly diagnosed
KMT2A-rearranged or
NPM1-mutant AML
(eligible for intensive chemotherapy)
KMT2A-rearranged or
NPM1-mutant AML
(eligible for intensive chemotherapy)
HOVON 181 AML/AML SG 37-25
Phase
NCT07223814
Compound
Bleximenib (menin inhibitor) + cytarabine + daunorubicin or idarubicin
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; AML, acute myeloid leukemia; CALR, calreticulin; CD, cluster of differentiation; KMT2A, lysine methyltransferase 2A; MDS, myelodysplastic neoplasms; NPM1, nucleophosmin 1; NUP98, nucleoporin 98; NUP214, nucleoporin 214; Vδ2, variable delta 2.